Company Enliven Therapeutics, Inc.

Equities

ELVN

US29337E1029

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 12/07/2024 BST 5-day change 1st Jan Change
24.74 USD +2.83% Intraday chart for Enliven Therapeutics, Inc. +10.35% +78.76%

Business Summary

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.

Number of employees: 50

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 47,036,698 43,850,000 ( 93.23 %) 0 93.23 %

Shareholders

NameEquities%Valuation
OrbiMed Advisors Private Equity
16.92 %
7,959,538 16.92 % 186 M $
Fidelity Management & Research Co. LLC
13.28 %
6,246,293 13.28 % 146 M $
Venrock Associates
8.560 %
4,026,331 8.560 % 94 M $
Commodore Capital LP
8.447 %
3,973,245 8.447 % 93 M $
5AM Venture Management LLC
8.155 %
3,835,975 8.155 % 90 M $
Fairmount Funds Management LLC
6.809 %
3,202,798 6.809 % 75 M $
Citadel Securities GP LLC
5.005 %
2,354,403 5.005 % 55 M $
RA Capital Management LP
4.512 %
2,122,465 4.512 % 50 M $
BlackRock Advisors LLC
3.573 %
1,680,405 3.573 % 39 M $
Logos Global Management LP
3.347 %
1,574,220 3.347 % 37 M $

Company contact information

Enliven Therapeutics, Inc.

6200 Lookout Road

80301, Boulder

+

http://www.enliventherapeutics.com
address Enliven Therapeutics, Inc.(ELVN)
  1. Stock Market
  2. Equities
  3. ELVN Stock
  4. Company Enliven Therapeutics, Inc.